Haemonetics (HAE) Projected to Post Earnings on Thursday

Haemonetics (NYSE:HAE - Get Free Report) is projected to post its Q4 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Haemonetics to post earnings of $1.22 per share and revenue of $329.38 million for the quarter. Haemonetics has set its FY 2025 guidance at 4.500-4.700 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Trading Up 1.8 %

Shares of HAE stock traded up $1.15 during trading hours on Tuesday, reaching $63.64. 683,830 shares of the stock were exchanged, compared to its average volume of 692,110. Haemonetics has a 12-month low of $55.30 and a 12-month high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $3.20 billion, a price-to-earnings ratio of 25.06, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company's 50-day moving average price is $62.67 and its 200-day moving average price is $71.54.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HAE. JMP Securities lowered their price objective on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research report on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. StockNews.com raised shares of Haemonetics from a "hold" rating to a "buy" rating in a research note on Monday. Barrington Research reduced their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Finally, Needham & Company LLC lowered their target price on Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.